BDNF prevents NMDA-induced toxicity in models of Huntington's disease: The effects are genotype specific and adenosine A2A receptor is involved

Journal of Neurochemistry

Volumn 125, Issue 2, 2013, Pages 225-235

  Martire, Alberto ^a   Pepponi, Rita ^a   Domenici, Maria Rosaria ^a   Ferrante, Antonella ^a   Chiodi, Valentina ^a   Popoli, Patrizia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Adenosine A2A receptors; brain derived neurotrophic factor; Huntington's disease; NMDA; R6 2 mice; striatum

Indexed keywords

ADENOSINE A2A RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; HUNTINGTIN; N METHYL DEXTRO ASPARTIC ACID; N METHYLASPARTIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN ELECTROPHYSIOLOGY; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; EXCITOTOXICITY; FEMALE; GENOTYPE; HUNTINGTON CHOREA; IN VITRO STUDY; MALE; MOUSE; NERVE POTENTIAL; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; WHOLE CELL; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; METABOLISM; PATCH CLAMP TECHNIQUE; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

MUS;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; FEMALE; GENOTYPE; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; N-METHYLASPARTATE; PATCH-CLAMP TECHNIQUES; RECEPTOR, ADENOSINE A2A; SYNAPTIC TRANSMISSION;

EID: 84876119829     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12177     Document Type: Article

References (50)

1. Ali N. J., and, Levine M. S., (2006) Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 moue model of Huntington disease. Dev. Neurosci. 28, 230-238.
2. Anderson W. W., and, Collingridge G. L., (2001) The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J. Neurosci. Methods 15, 71-83.
3. Bemelmans A. P., Horellou P., Pradier L., Brunet I., Colin P., and, Mallet J., (1999) Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther. 10, 2987-2997.
4. Caldeira M. V., Melo C. V., Pereira D. B., Carvalho R. F., Carvalho A. L., and, Duarte C. B., (2007) BDNF regulates the expression and traffic of NMDA receptors in cultured hippocampal neurons. Mol. Cell. Neurosci. 35, 208-219.
5. Cattaneo E., and, Conti L., (1998) Generation and characterization of embryonic striatal conditionally immortalized ST14A cells. J. Neurosci. Res. 53, 223-234.
6. Cattaneo E., Zuccato C., and, Tartari M., (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6, 919-930.
7. Cepeda C., Colwell C. S., Itri J. N., Gruen E., and, Levine M. S., (1998) Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons. Eur. J. Neurosci. 10, 3491-3497.
8. Cepeda C., Ariano M. A., Calvert C. R., Flores-Hernández J., Chandler S. H., Leavitt B. R., Hayden M. R., and, Levine M. S., (2001) NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66, 525-539.
9. Cha J. H., Frey A. S., Alsdorf S. A., Kerner J. A., Kosinski C. M., Mangiarini L., Penney J. B., Jr, Davies S. W., Bates G. P., and, Young A. B., (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 354, 981-989.
10. Crozier R. A., Bi C., Han Y. R., and, Plummer M. R., (2008) BDNF modulation of NMDA receptors is activity dependent. J. Neurophysiol. 100, 3264-3274.
11. Cull-Candy S., Brickley S., and, Farrant M., (2001) NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 11, 327-335.
12. Dingledine R., Borges K., Bowie D., and, Traynelis S. F., (1999) The glutamate receptor ion channels. Pharmacol. Rev. 51, 7-61.
13. 2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J. Neurosci. 24, 2905-2913.
14. 2A receptors. Hippocampus 17, 577-585.
15. 2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol. Dis. 28, 197-205.
16. Ehrlich M. E., Conti L., Toselli M., et al,. (2001) ST14A cells have properties of a medium-size spiny neuron. Exp. Neurol. 167, 215-226.
17. 2A receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice. Brain Res. 1323, 184-191.
18. Gauthier L. R., Charrin B. C., Borrell-Pages M., et al,. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127-138.
19. Gavalda N., Perez-Navarro E., Gratacos E., Comella J. X., and, Alberch J., (2004) Differential involvement of phosphatidylinositol 3-kinase and p42/p44 mitogen activated protein kinase pathways in brain-derived neurotrophic factor induced trophic effects on cultured striatal neurons. Mol. Cell. Neurosci. 25, 460-468.
20. Glass M., Dragunow M., and, Faull R. L., (2000) The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505-519.
21. Gomes J. R., Costa J. T., Melo C. V., et al,. (2012) Excitotoxicity downregulates TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons. J. Neurosci. 32, 4610-4622.
22. Heng M. Y., Detloff P. J., Wang P. L., Tsien J. Z., and, Albin R. L., (2009) In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J. Neurosci. 29, 3200-3205.
23. Ji Y., Lu Y., Yang F., Shen W., Tang T. T., Feng L., Duan S., and, Lu B., (2010) Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. Nat. Neurosci. 13, 302-309.
24. Knüsel B., and, Hefti F,. (1992) K-252 compounds: modulators of neurotrophin signal transduction. J. Neurochem. 59, 1987-1996.
25. Lee F. S., and, Chao M. V., (2001) Activation of trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl Acad. Sci. USA 98, 3555-3560.
26. Levine M. S., Klapstein G. J., Koppel A., et al,. (1999) Enhanced sensitivity to N-methyl-D aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58, 515-532.
27. Liu Y., Wong T. P., Aarts M., et al,. (2007) NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 27, 2846-2857.
28. Mangiarini L., Sathasivam K., Seller M., et al,. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
29. 2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice. Neurosci. Lett. 417, 78-83.
30. 2A receptor blockade in Huntington's disease mice. Neurobiol. Dis. 37, 99-105.
31. 2A receptor antagonist SCH58621 on cyclooxygenase-2 expression, glial activation and BDNF availability in a rat model of striatal neurodegeneration. J. Neuropathol. Exp. Neurol. 66, 363-371.
32. Pattwell S. S., Bath K. G., Perez-Castro R., Lee F. S., Chao M. V., and, Ninan I., (2012) The BDNF Val66Met polymorphism impairs synaptic transmission and plasticity in the infralimbic medial prefrontal cortex. J. Neurosci. 32, 2410-2421.
33. 2A receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease. Purinergic Signal. 3, 333-338.
34. 2A receptors. Neurosci. Lett. 404, 143-147.
35. Reddy P. H., Charles V., Williams M., Miller G., Whetsell W. O., Jr, and, Tagle D. A., (1999) Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 354, 1035-1045.
36. Tapley P., Lamballe F., and, Barbacid M., (1992) K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene 7, 371-381.
37. Tarditi A., Camurri A., Varani K., Borea P. A., Woodman B., Bates G., Cattaneo E., and, Abbracchio M. P., (2006) Early and transient alteration of adenosine A(2A) receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 23, 44-53.
38. 2A receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J. Neurochem. 104, 279-286.
39. 2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum. J. Neurochem. 110, 1921-1930.
40. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
41. del Toro D., Canals J. M., Gines S., Kojima M., Egea G., and, Alberch J., (2006) Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. J. Neurosci. 26, 12748-12757.
42. Torres-Peraza J. F., Giralt A., García-Martínez J. M., Pedrosa E., Canals J. M., and, Alberch J., (2008) Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling. Neurobiol. Dis. 29, 409-421.
43. Traficante A., Riozzi B., Cannella M., Rampello L., Squitieri F., and, Battaglia G,. (2007) Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease. NeuroReport. 18, 1997-2000.
44. 2A receptor signaling in striatal cells expressing mutant Huntingtin. FASEB J. 15, 1245-1247.
45. 2A receptor function in peripheral blood cells in Huntington's disease. FASEB J. 17, 2148-2150.
46. Vonsattel J. P., and, DiFiglia M., (1998) Huntington disease. J. Neuropathol. Exp. Neurol. 57, 369-384.
47. Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D., and, Richardson E. P., Jr, (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577.
48. Zeron M. M., Hansson O., Chen N., Wellington C. L., Leavitt B. R., Brundin P., Hayden M. R., and, Raymond L. A., (2002) Increased sensitivity to N-methyl-D-aspartate receptor mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849-860.
49. Zuccato C., and, Cattaneo E., (2007) Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 81, 294-330.
50. Zuccato C., Ciammola A., Rigamonti D., et al,. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498.